Enliven Therapeutics, founded in 2019, focuses on the discovery and development of small molecule kinase inhibitors to treat cancer patients. The company's precision oncology approach combines clinically validated biological targets and industry-leading chemistry to address the limitations of existing therapies, with the goal of improving patient survival and well-being. Enliven's discovery process aims to design potentially first-in-class or best-in-class therapies to meet existing and emerging unmet needs in the healthcare sector.